5 completed, 1 not yet recruiting, 1 recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow EGFR Mutation: new trials by email Literature Review of EGFR Mutation trials Research Report on EGFR Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability Company | 253 | 2026-06-01 | 2025-12-16 |
| A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants BAY2927088, Midazolam - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 15 | 2024-04-17 | 2024-07-03 |
| A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants BAY2927088, Itraconazole, Carbamazepine - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 30 | 2024-04-10 | 2024-06-20 |
| A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants BAY2927088, Esomeprazole, Food - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 21 | 2024-03-29 | 2024-07-05 |
| A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants BAY2927088, Dabigatran etexilate, Rosuvastatin - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 15 | 2024-03-25 | 2024-07-05 |
| A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants BAY2927088 coated tablet 10 mg, [14C]-BAY2927088 solution for infusion, [14C]-BAY2927088 oral solution - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 8 | 2024-01-25 | 2024-06-28 |
| First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2 - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Recruiting | Bayer | 430 | 2021-10-25 | 2026-10-21 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Lung Neoplasms (1)
Carbamazepine (1) · Dabigatran (1) · Esomeprazole (1) · Food (1) · Itraconazole (1) · Midazolam (1) · Rosuvastatin Calcium (1) · osimertinib (1)
Bayer (6) · Beijing Pearl Biotechnology Limited Liability Company (1)
United States (5) · Netherlands (2) · Belgium (1) · Brazil (1) · China (1) · France (1) · Hong Kong (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1) · Portugal (1) · Singapore (1) · South Korea (1) · Spain (1)
2023 (1)